Gertz Morie A, Lacy Martha Q, Dispenzieri Angela, Hayman Suzanne R, Kumar Shaji
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Curr Opin Oncol. 2007 Mar;19(2):136-41. doi: 10.1097/CCO.0b013e32801494c6.
High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature.
We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial.
Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.
大剂量化疗越来越多地用于免疫球蛋白轻链淀粉样变性患者的治疗。我们描述了近300例在梅奥诊所接受大剂量化疗联合干细胞移植治疗的患者，并回顾了近期文献。
我们回顾了治疗结果、植入数据以及早期死亡率的预测因素。然而，移植的生存获益尚未在III期临床试验中得到验证。
部分缓解率和完全缓解率是淀粉样变性患者生存的预后指标。接受大剂量治疗和移植的患者这些比率要高得多。
